

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

NOTICE OF THE 2025 ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2025 annual general meeting (the “AGM”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) will be held at 2:00 p.m. on Friday, May 22, 2026 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanshan Boulevard, Nanshan District, Shenzhen, the PRC for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the circular of the Company dated April 29, 2026.

ORDINARY RESOLUTIONS

To consider and pass the following ordinary resolutions by way of non-cumulative voting:

- 1.00. The resolution regarding receiving and considering the audited accounts, the Directors’ Report and the Auditor’s Report for the year ended December 31, 2025;
- 2.00. The resolution regarding the 2025 Profit Distribution Proposal of the Company;
- 3.00. The resolution regarding the confirmation of Directors’ Remuneration for 2025 and Remuneration Plan for 2026;
- 4.00. The resolution regarding the re-appointment of auditor of the Company;
- 5.00. The resolution regarding the change in the use of proceeds from the issuance of H Shares;

6.00. The resolution regarding the conducting of Foreign Exchange Derivative Transactions for Hedging Purposes;

7.00. The resolution regarding the remuneration of Directors and allowances for Independent Directors of the Seventh Session of the Board;

To consider and pass the following ordinary resolutions by way of cumulative voting:

8.01. The resolution regarding the re-election of Mr. Li Li as an executive Director;

8.02. The resolution regarding the re-election of Ms. Li Tan as an executive Director;

8.03. The resolution regarding the re-election of Mr. Shan Yu as an executive Director;

9.01. The resolution regarding the re-election of Mr. Huang Peng as an independent non-executive Director;

9.02. The resolution regarding the re-election of Mr. Yi Ming as an independent non-executive Director;

9.03. The resolution regarding the re-election of Mr. Pu Hong as an independent non-executive Director;

SPECIAL RESOLUTIONS

To consider and pass the following special resolutions by way of non-cumulative voting:

10.00. The resolution regarding the Company's purchase of wealth management products and cash flow management using internal funds; and

11.00. The resolution regarding the Company's application for credit line and providing guarantee to the banks for 2026.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
April 29, 2026

Notes:

1. The register of members of the Company's H shares will be closed from Saturday, May 16, 2026 to Friday, May 22, 2026 (both days inclusive), during which period no transfer of H shares will be effected. In order for H share shareholders to be qualified to attend and vote at the AGM, all transfer documents accompanied by the relevant share certificates must be lodged with the H Shares registrar of the Company, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, no later than 4:30 p.m. on Friday, May 15, 2026 for registration.

The H share shareholders whose names appear on the register of members of the Company's H shares on Friday, May 22, 2026 are entitled to attend and vote at the AGM.

2. H share shareholders who are entitled to attend and vote at the AGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a shareholder.
3. The instrument appointing a proxy must be in writing under the hand of a shareholder or his/her attorney duly authorised in writing. If the shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.
4. In order to be valid, the proxy form must be deposited, for H share shareholders, to the H Shares registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 24 hours before the time for holding the AGM. If the proxy form is signed by a person under a power of attorney or other authority, a notarized copy of that power of attorney or other authority shall be deposited at the same time as mentioned in the proxy form. Completion and return of the proxy form will not preclude the shareholders from attending and voting in person at the AGM or any adjourned meetings should they so wish.
5. Shareholders shall produce their identification documents and supporting documents in respect of the shares of the Company held when attending the AGM. If corporate shareholders appoint authorised representative to attend the AGM, the authorised representative shall produce his/her identification documents and a notarized copy of the relevant authorisation instrument signed by the board of directors or other authorised parties of the corporate shareholders or other notarized documents allowed by the Company. Proxies shall produce their identification documents and the proxy form signed by the shareholders or their attorney when attending the AGM.
6. The AGM is expected to take for less than half a day. Shareholders attending the AGM shall be responsible for their own travel and accommodation expenses.

7. In respect of the resolutions 8 and 9, cumulative voting system shall be adopted. Please indicate by inserting the number of votes in the space provided as to how you wish your votes to be cast.

The number of candidates for the executive Directors or independent non-executive Directors may be greater than that of the executive Directors or independent non-executive Directors to be elected at the AGM, but the number of candidates to be voted by each H shares Shareholder shall not exceed the number of executive Directors or independent non-executive Directors to be elected at the AGM, and the total number of votes allocated to the H shares Shareholders shall not exceed the number of votes held by them; otherwise, the votes shall be invalid.

Voting for executive Directors and independent non-executive Directors shall be carried out separately. For the election of executive Directors, the number of votes each H shares Shareholder is entitled to shall be equal to the number of shares held by the H shares Shareholder multiplied by the number of executive Directors to be elected, and such votes must be cast only for the candidates for the role of the Company's executive Directors; for the election of independent non-executive Directors, the number of votes each H shares Shareholder is entitled to shall be equal to the number of shares held by the H shares Shareholder multiplied by the number of independent non-executive Directors to be elected, and such votes must be cast only for the candidates for the role of the Company's independent non-executive Directors.

The candidates to be finally elected as executive Directors or independent non-executive Directors shall be determined according to the numbers of votes they have received, but the minimum number of votes each candidate elected has received must exceed half of the total number of shares held by H shares Shareholders (including proxies thereof) attending the AGM. If the number of executive Directors or independent non-executive Directors elected falls short of the number of executive Directors or independent non-executive Directors to be elected at the AGM, a new round of voting shall be carried out for the candidates for the roles of executive Directors or independent non-executive Directors not having received the required number of votes to fill the shortage. If the shortage is still not filled, a by-election shall be conducted at the next AGM of the Company. If two or more candidates for the roles of executive Directors or independent non-executive Directors have the same number of votes, but not all of them can be elected according to the election quota, a separate round of voting shall be conducted for such candidates with the same number of votes.

The total number of votes cast by you for one or several Directors candidates shall not be in excess of the number of votes to which you are entitled, otherwise such vote shall be invalid. Where the total number of votes cast for one or several Directors candidate(s) is less than the number of votes to which you are entitled, such vote shall be valid, and the voting rights attached to the difference between the votes actually cast and the votes which you are entitled to cast shall be deemed to have been waived.

8. All voting at the AGM will be conducted by poll.
9. References to times and dates of this notice are to Hong Kong times and dates.

As at the date of this notice, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.